

Curriculum Vitae

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N. 53rd Street, Temple Terrace, FL 33617
Office 813.948.7550 | MooreCR.com | Fax 813.948.7566

Research & Professional Experience:	
MOORE Clinical Research, Inc, Clinical Investigator	March 2018-Present
Clearwater Free Care Clinic, Internist, Clearwater, Florida	Jan 2017-Present
Industrial Medical Associates, Internal Medicine Evaluations, St Petersburg, Florida	April 2017-2018
American Well, Internal Medicine Telemedicine, Boston, Massachusetts	March 2017-Present
Managing Partner Allergy and Asthma Specialists, PC, Boston, Massachusetts	July 1983-Dec 2016
Principal Investigator, Certified Research Consultants, Boston, Massachusetts	Jan 1984-June 2012
Clinical Associate, Harvard Medical School, Department of Medicine, Mass General Hospital	1986-2000
Assistant Professor, Harvard Medical School, MA	1983
Instructor in Pediatrics, Harvard Medical School, Assistant in Medicine Brigham & Women’s Hospital and Children’s Hospital Medical Center, Boston MA	1981-1982
Lecturer, Clinical Physiology, University of the Witwatersrand Medical School, Johannesburg	1973-1974
Instructor, Gross Anatomy, University of Witwatersrand Medical School, Johannesburg	1969-1971

Education and Postdoctoral Training:	
Fellow in Allergy, Department of Cell Biology, Children’s Hospital Center and Brigham and Women’s Hospital, Harvard Medical School	July 1979-June 1981
Fellow in Allergy and Clinical Immunology, Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York	Jan 1975-June 1977
Associate in Biochemistry and Junior Lecturer in Physiology, University of Witwatersrand Medical School, Johannesburg, South Africa	Jan 1974-Dec 1974
Resident in Internal Medicine, Hahnemann Medical School, Philadelphia, PA	July 1977-June 1979
Intern in Internal Medicine, Johannesburg General Hospital, University of Witwatersrand, Johannesburg, South Africa	Jan 1973-Dec 1976
University of Witwatersrand, Medical Doctor, Johannesburg, South Africa	Dec 1972
University of Witwatersrand, Bachelors of Science, Johannesburg, South Africa	Dec 1968

Licenses/Certifications/Memberships:	
Educational Commission for Foreign Medical Graduates Certification Number 1829605	Issued 1972
State of Florida Medical License ME 119142	January 2020
Diplomat, American Board of Internal Medicine	September 1979
Diplomat, American Board of Allergy and Clinical Immunology	October 1981
Bloodborne Pathogens & Biomedical Waste Management 29 CFR OSHA Regulations	August 2020
BLS for Healthcare Providers, American Heart Association	March 2020
NPI Number 1083618995	
DEA Number AM9173991	

Training:	
Comprehensive SOP Review	January 2020
Bloodborne Pathogens & Biomedical Waste Management	August 2019
Comprehensive SOP Review	January 2019
KOH Wet Mount and Mycology Sample Collection and Interpretation	July 2018
Adverse Events Collection and Reporting in Clinical Research	May 2018

Note: Electronic signature for this document is a Part 11 compliant signature produced via RealTime CTMS eDOCS

Curriculum Vitae

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N. 53rd Street, Temple Terrace, FL 33617
Office 813.948.7550 | MooreCR.com | Fax 813.948.7566

Acne Vulgaris Rater Training and Validation	April 2018
Bloodborne Pathogens & Biomedical Waste Management	March 2018
Comprehensive SOP Review	March 2018
HIPAA Training	March 2018
Responsible Conduct of Research, CITI Program	March 2018
Good Clinical Practice, NIH Training	March 2018
Human Subject Assurance Training	March 2018

Clinical Trial Experience:

Asthma, Allergy, Atopic Dermatitis, Clinical Trials, Principal Investigator for numerous clinical trials, Managing Partners Allergy and Asthma Specialists, PC, Boston, MA, 1982-2012

ACNE VULGARIS (Validated Acne Rater)

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Adapalene Gel 0.1% (XXXX) to Differin Gel (Adapalene 0.1% XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2020, Sub-Investigator

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Tretinoin Cream 0.025% (XXXX) to Retin-A® (Tretinoin) Cream 0.025% and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2019, Sub-Investigator

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Clindamycin Phosphate Topical Lotion 1% (XXXX) to Clindamycin Phosphate Topical Lotion 1% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2019, Sub-Investigator

"A Multi-Center, Double-Blind, Randomized, Three-Arm, Placebo Controlled, Parallel-Group Study, Comparing Dapsone Gel, 7.5% (XXXX) to Aczone® (Dapsone) Gel, 7.5% (XXXX) and Both Active Treatments to A Placebo Control in the Treatment of Acne Vulgaris." 2019, Sub-Investigator

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Clindamycin Phosphate Topical Gel 1% (XXXX) to Cleocin T (Clindamycin Phosphate Topical Gel 1% XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2019 Sub-Investigator

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Adapalene Gel 0.3% (XXXX) to Differin® (XXXX, Adapalene Gel 0.3%) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2018, Sub-Investigator

"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of XXX XXX and Clindamycin Phosphate Lotion, 1% in Subjects with Acne Vulgaris." 2018 Principal Investigator

"A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study, Comparing Clindamycin 1% to Cleocin T (XXXX, Clindamycin 1% Gel) and Both Active Treatments to a Vehicle Control in the Treatment of Acne." 2018, Principal Investigator

ACTINIC KERATOSIS

"A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel Group Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream 5%, With Efudex (5-FU) Cream 5%, and Both Active Treatments to a Vehicle Control, in the Treatment of Actinic Keratosis." 2018 Sub-Investigator

Note: Electronic signature for this document is a Part 11 compliant signature produced via RealTime CTMS eDOCS

Curriculum Vitae

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N. 53rd Street, Temple Terrace, FL 33617
Office 813.948.7550 | MooreCR.com | Fax 813.948.7566

"A Randomized, Double-Blind, Placebo-Controlled, Three-Arm, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Diclofenac Sodium Gel 3% (XXXX) Compared to Solaraze® (diclofenac sodium) Gel 3% (XXXX) in the Treatment of Actinic Keratosis." 2017, Sub-Investigator

ASTHMA

"A Randomized, Double-Blind, Parallel Group, Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of XXXX to Placebo and Open-label Spiriva® Respimat® in Subjects with Persistent Asthma." 2018, Principal Investigator

"A Randomized, Blinded, Multiple-Dose, Placebo-Controlled, Multi-Center Study Comparing Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 mcg to QVAR® 40 mcg (beclomethasone dipropionate HFA), Inhalation Aerosol in Treatment of Subjects with Asthma." 2018, Principal Investigator

ATOPIC DERMATITIS

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Doxepin Hydrochloride Topical Cream, 5% (XXXX) to Doxepin Hydrochloride topical cream, 5% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Moderate Pruritis in Adults with Atopic Dermatitis." 2019, Principal Investigator

"Pilot Study of Explore LXR Receptor Engagement by ALX-101 Following Treatment of Moderate Atopic Dermatitis with ALX-101 Topical Gel and Vehicle Gel." 2018, Sub-Investigator

"A Multicenter, Randomized, Double-Blind, Bilateral, Vehicle-Controlled Study of a Topical Gel Administered Twice Daily in Adult and Adolescent Subjects with Moderate to Severe Atopic Dermatitis." 2017, Sub-Investigator

COMMON COLD

"A Phase 3, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of colds due to Enterovirus/Rhinovirus infection." 2018, Principal Investigator

INFLUENZA

"A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza." 2018, Principal Investigator

PSORIASIS

"A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Proof of Concept Comparison Study of the Safety and Efficacy of DUR-928 Topical Solution with Occlusion in Subjects with Mild to Moderate Plaque Psoriasis." 2019 Sub-Investigator

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Calcipotriol and Betamethasone Dipropionate Topical Gel 0.005%/0.064% (XXXX) Dovobet® Gel (Calcipotriol and Betamethasone Dipropionate Gel) 0.005%/0.064% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Mild to Moderate Body Plaque Psoriasis Vulgaris." 2018, Sub-Investigator

"A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis." 2018, Sub-Investigator

Note: Electronic signature for this document is a Part 11 compliant signature produced via RealTime CTMS eDOCS

Curriculum Vitae

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N. 53rd Street, Temple Terrace, FL 33617
Office 813.948.7550 | MooreCR.com | Fax 813.948.7566

"A Randomised, Multicentre, Investigator-Blind, Parallel-Group Trial to Evaluate the Efficacy and Safety of MC2-01 Cream Compared to MC2-01 Cream Vehicle and Active Comparator in Subjects with Mild-to-Moderate Psoriasis Vulgaris." 2017, Sub-Investigator

ROSACEA

"A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study, Comparing Ivermectin Cream 1% (XXXX) to Soolantra® (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Moderate to Severe Facial Rosacea." 2019, Principal Investigator

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Azelaic Acid Foam 15% (XXXX) to Finacea (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Moderate Facial Rosacea." 2017, Sub-Investigator

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Ivermectin Cream 1% (XXXX) to Soolantra® (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Moderate to Severe Facial Rosacea." 2017, Sub-Investigator

SCALP PSORIASIS

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension 0.005%/0.064% (XXXX) to Talconex® (Calcipotriene Hydrate and Betamethasone Dipropionate) Topical Suspension 0.005%.0.064% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Scalp Psoriasis." 2018, Sub-Investigator

TINEA PEDIS

"A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutics Equivalence of Ketoconazole Cream 2% (XXXX) to Ketoconazole 2% (XXXX) in the Treatment of Tinea Pedis." 2019, Sub-investigator

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Clotrimazole and Betamethasone Dipropionate Cream 1%/0.064% (XXXX) to Lotriderm (Clotrimazole and Betamethasone Dipropionate) Cream 1%/0.064% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Tinea Pedis." 2018, Sub-Investigator

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study, Comparing Naftifine HCL Gel 2% (XXXX) to Naftin (Naftifine HCL) Gel, 2% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Tinea Pedis." 2017, Sub-Investigator